Neumora Therapeutics, Inc. Common Stock
NMRANASDAQHealthcare● Active
$1.62
$-0.01(-0.61%)
Market Cap$300160469
P/E Ratio—
52W High$3.65
52W Low$0.716
Neumora Therapeutics, Inc. Common Stock (NMRA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NMRA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.30
Est. -$0.32 · +6.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
NMRA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.23 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.32 | -$0.30 | +6.3% | — | — | — |
| ▼ Q1 FY2026 | Mar 16, 2026 | -$0.34 | -$0.35 | -2.9% | — | — | — |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.34 | -$0.35 | -2.9% | — | — | — |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.38 | -$0.33 | +13.2% | — | — | — |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.40 | -$0.42 | -5.0% | — | — | — |
| ▲ Q1 FY2025 | Mar 3, 2025 | -$0.46 | -$0.37 | +19.6% | — | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.38 | -$0.45 | -18.4% | — | — | — |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.30
EPS Est.
-$0.32
EPS Surpr.
+6.3%
Revenue
—
Q1 FY2026
Mar 16, 2026Miss
EPS Actual
-$0.35
EPS Est.
-$0.34
EPS Surpr.
-2.9%
Revenue
—
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.35
EPS Est.
-$0.34
EPS Surpr.
-2.9%
Revenue
—
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
-$0.33
EPS Est.
-$0.38
EPS Surpr.
+13.2%
Revenue
—
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.42
EPS Est.
-$0.40
EPS Surpr.
-5.0%
Revenue
—
Q1 FY2025
Mar 3, 2025Beat
EPS Actual
-$0.37
EPS Est.
-$0.46
EPS Surpr.
+19.6%
Revenue
—
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.45
EPS Est.
-$0.38
EPS Surpr.
-18.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.23 | $-0.23 | $-0.23 | 2 |
| Q3 FY2027 | $-0.21 | $-0.21 | $-0.21 | 2 |
| Q2 FY2027 | $-0.19 | $-0.19 | $-0.19 | 2 |
| Q1 FY2027 | $-0.19 | $-0.19 | $-0.19 | 2 |
| Q4 FY2026 | $-0.21 | $-0.21 | $-0.21 | 4 |
| Q3 FY2026 | $-0.33 | $-0.23 | $-0.19 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +6.3% | $2.33 | $1.94 | -16.74% |
| ▼ Q1 FY2026 | Mar 16, 2026 | -2.9% | $3.00 | $2.87 | -4.33% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -2.9% | $2.62 | $2.58 | -1.53% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +13.2% | $1.66 | $1.59 | -4.22% |
| ▼ Q2 FY2025 | May 12, 2025 | -5.0% | $0.66 | $0.69 | +4.47% |
| ▲ Q1 FY2025 | Mar 3, 2025 | +19.6% | $1.56 | $1.41 | -9.62% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -18.4% | $13.64 | $11.31 | -17.08% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +0.0% | $11.96 | $11.99 | +0.25% |
Q2 FY2026-16.74%
Report Date
May 7, 2026
EPS Beat/Miss
+6.3%
Price Before
$2.33
Price After
$1.94
Q1 FY2026-4.33%
Report Date
Mar 16, 2026
EPS Beat/Miss
-2.9%
Price Before
$3.00
Price After
$2.87
Q4 FY2025-1.53%
Report Date
Nov 6, 2025
EPS Beat/Miss
-2.9%
Price Before
$2.62
Price After
$2.58
Q3 FY2025-4.22%
Report Date
Aug 6, 2025
EPS Beat/Miss
+13.2%
Price Before
$1.66
Price After
$1.59
Q2 FY2025+4.47%
Report Date
May 12, 2025
EPS Beat/Miss
-5.0%
Price Before
$0.66
Price After
$0.69
Q1 FY2025-9.62%
Report Date
Mar 3, 2025
EPS Beat/Miss
+19.6%
Price Before
$1.56
Price After
$1.41
Q4 FY2024-17.08%
Report Date
Nov 12, 2024
EPS Beat/Miss
-18.4%
Price Before
$13.64
Price After
$11.31
Q3 FY2024+0.25%
Report Date
Aug 6, 2024
EPS Beat/Miss
+0.0%
Price Before
$11.96
Price After
$11.99
Avg Beat Reaction-7.58%
Avg Miss Reaction-4.62%
Beat Rate4 / 8 quarters
Largest Move-17.08% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NMRA ends December
Neumora Therapeutics, Inc. Common Stock (NMRA) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.30 — beating the analyst consensus of $-0.32 by +6.3%. The next NMRA earnings date is expected around September 1, 2026.
Each quarter, investors track NMRA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NMRA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NMRA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NMRA earnings · 5 questionsNeumora Therapeutics, Inc. Common Stock's next earnings report is expected around September 1, 2026. NMRA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NMRA historically reports after market close (AMC).
NMRA earnings datewhen is NMRA earningsNMRA next earnings datewhen does NMRA report earningsNMRA earnings calendar
▸ Source: FMP · Neumora Therapeutics, Inc. Common Stock SEC filings · US GAAP · Neumora Therapeutics, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026